Predicting bacteraemia or rapid identification of the causative pathogen in community acquired pneumonia: where should the priority lie?

Community-acquired pneumonia (CAP) remains amongst the most common causes of infectious disease-related death worldwide. However, despite its clinical importance the existing routine microbiology tests for CAP pathogens have significant limitations, lacking sensitivity for identifying the causative...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The European respiratory journal 2016-09, Vol.48 (3), p.619-622
Hauptverfasser: José, Ricardo J, Brown, Jeremy S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 622
container_issue 3
container_start_page 619
container_title The European respiratory journal
container_volume 48
creator José, Ricardo J
Brown, Jeremy S
description Community-acquired pneumonia (CAP) remains amongst the most common causes of infectious disease-related death worldwide. However, despite its clinical importance the existing routine microbiology tests for CAP pathogens have significant limitations, lacking sensitivity for identifying the causative pathogen and only altering management in a minority of patients. For example, blood cultures identify a pathogen in less than or equal to 10% of CAP cases [1, 2] and results are usually only available after 24h. Therefore, clinicians are still required to prescribe broad-spectrum antibiotics for the first 24-72h, which is the period of highest risk for clinical deterioration and death [3, 4]; even when bacteria are cultured this only rarely leads to a change in treatment and may miss co-infection [2, 5]. These limitations have led to suggestions that patients admitted with CAP do not require routine microbiological testing with management decisions based solely on clinical factors. However, not identifying the causative pathogens in CAP has important implications. From a public health perspective, not performing microbiological testing could result in failure to identify important changes in microbial aetiology or changes in anti-microbial resistance patterns. In the absence of microbiological testing all patients would be treated with prolonged broad-spectrum antibiotics that may not be required if, for example, Streptococcus pneumoniae was the causative pathogen, thereby unnecessarily increasing drug cost and potentially promoting the development of antimicrobial resistance or anti-microbial-related complications such as Clostridium difficile diarrhoea [6]. Finally, the relatively rare CAP patient infected with a drug-resistant pathogen, such as community-acquired methicillin-resistant Staphylococcus aureus or Pseudomonas aeruginosa, may not be identified, thus increasing the chance of a poor outcome.
doi_str_mv 10.1183/13993003.00941-2016
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1827920170</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1827920170</sourcerecordid><originalsourceid>FETCH-LOGICAL-c383t-5d1f26bf5e93f26bf4e3461c1c136c0395f3ab369309b9c071d7d242e0ae4e753</originalsourceid><addsrcrecordid>eNqNkc9O3DAQxi1U1N1CnwCp8rGXgJ1xnHUvVbXqHyQkOMA5cpzJrqvEDrYD4g362DgL9Izm4NGn33wjz0fIGWfnnG_ggoNSwBicM6YEL0rG5RFZL2qxyB_ImikGBVcgV-RTjH9ZJgTwj2RV1tWGCybX5N9NwM6aZN2OttokDBpHq6kPNOjJdtR26JLtrdHJekd9T9MeqdFzzMID0kmnvd-ho9ZR48dxdjY9UW3uZ5ud6eRwHr2z-ht93GNAGvd-HrqDyRSsDws9WPx-So57PUT8_PqekLtfP2-3f4qr69-X2x9XhYENpKLqeF_Ktq9QwaERCEJykwukYaCqHnQLMl9Gtcqwmnd1V4oSmUaBdQUn5OuL7xT8_YwxNaONBodBO_RzbPimrFW-Zc3egXIpQdRKZBReUBN8jAH7Jn9u1OGp4axZ0mre0moOaTVLWnnqy-uCuR2x-z_zFg88A_VlkZQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1816634794</pqid></control><display><type>article</type><title>Predicting bacteraemia or rapid identification of the causative pathogen in community acquired pneumonia: where should the priority lie?</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>José, Ricardo J ; Brown, Jeremy S</creator><creatorcontrib>José, Ricardo J ; Brown, Jeremy S</creatorcontrib><description>Community-acquired pneumonia (CAP) remains amongst the most common causes of infectious disease-related death worldwide. However, despite its clinical importance the existing routine microbiology tests for CAP pathogens have significant limitations, lacking sensitivity for identifying the causative pathogen and only altering management in a minority of patients. For example, blood cultures identify a pathogen in less than or equal to 10% of CAP cases [1, 2] and results are usually only available after 24h. Therefore, clinicians are still required to prescribe broad-spectrum antibiotics for the first 24-72h, which is the period of highest risk for clinical deterioration and death [3, 4]; even when bacteria are cultured this only rarely leads to a change in treatment and may miss co-infection [2, 5]. These limitations have led to suggestions that patients admitted with CAP do not require routine microbiological testing with management decisions based solely on clinical factors. However, not identifying the causative pathogens in CAP has important implications. From a public health perspective, not performing microbiological testing could result in failure to identify important changes in microbial aetiology or changes in anti-microbial resistance patterns. In the absence of microbiological testing all patients would be treated with prolonged broad-spectrum antibiotics that may not be required if, for example, Streptococcus pneumoniae was the causative pathogen, thereby unnecessarily increasing drug cost and potentially promoting the development of antimicrobial resistance or anti-microbial-related complications such as Clostridium difficile diarrhoea [6]. Finally, the relatively rare CAP patient infected with a drug-resistant pathogen, such as community-acquired methicillin-resistant Staphylococcus aureus or Pseudomonas aeruginosa, may not be identified, thus increasing the chance of a poor outcome.</description><identifier>ISSN: 0903-1936</identifier><identifier>EISSN: 1399-3003</identifier><identifier>DOI: 10.1183/13993003.00941-2016</identifier><identifier>PMID: 27581406</identifier><language>eng</language><publisher>England</publisher><subject>Clostridium difficile ; Pseudomonas aeruginosa ; Staphylococcus aureus ; Streptococcus pneumoniae</subject><ispartof>The European respiratory journal, 2016-09, Vol.48 (3), p.619-622</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c383t-5d1f26bf5e93f26bf4e3461c1c136c0395f3ab369309b9c071d7d242e0ae4e753</citedby><cites>FETCH-LOGICAL-c383t-5d1f26bf5e93f26bf4e3461c1c136c0395f3ab369309b9c071d7d242e0ae4e753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27581406$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>José, Ricardo J</creatorcontrib><creatorcontrib>Brown, Jeremy S</creatorcontrib><title>Predicting bacteraemia or rapid identification of the causative pathogen in community acquired pneumonia: where should the priority lie?</title><title>The European respiratory journal</title><addtitle>Eur Respir J</addtitle><description>Community-acquired pneumonia (CAP) remains amongst the most common causes of infectious disease-related death worldwide. However, despite its clinical importance the existing routine microbiology tests for CAP pathogens have significant limitations, lacking sensitivity for identifying the causative pathogen and only altering management in a minority of patients. For example, blood cultures identify a pathogen in less than or equal to 10% of CAP cases [1, 2] and results are usually only available after 24h. Therefore, clinicians are still required to prescribe broad-spectrum antibiotics for the first 24-72h, which is the period of highest risk for clinical deterioration and death [3, 4]; even when bacteria are cultured this only rarely leads to a change in treatment and may miss co-infection [2, 5]. These limitations have led to suggestions that patients admitted with CAP do not require routine microbiological testing with management decisions based solely on clinical factors. However, not identifying the causative pathogens in CAP has important implications. From a public health perspective, not performing microbiological testing could result in failure to identify important changes in microbial aetiology or changes in anti-microbial resistance patterns. In the absence of microbiological testing all patients would be treated with prolonged broad-spectrum antibiotics that may not be required if, for example, Streptococcus pneumoniae was the causative pathogen, thereby unnecessarily increasing drug cost and potentially promoting the development of antimicrobial resistance or anti-microbial-related complications such as Clostridium difficile diarrhoea [6]. Finally, the relatively rare CAP patient infected with a drug-resistant pathogen, such as community-acquired methicillin-resistant Staphylococcus aureus or Pseudomonas aeruginosa, may not be identified, thus increasing the chance of a poor outcome.</description><subject>Clostridium difficile</subject><subject>Pseudomonas aeruginosa</subject><subject>Staphylococcus aureus</subject><subject>Streptococcus pneumoniae</subject><issn>0903-1936</issn><issn>1399-3003</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqNkc9O3DAQxi1U1N1CnwCp8rGXgJ1xnHUvVbXqHyQkOMA5cpzJrqvEDrYD4g362DgL9Izm4NGn33wjz0fIGWfnnG_ggoNSwBicM6YEL0rG5RFZL2qxyB_ImikGBVcgV-RTjH9ZJgTwj2RV1tWGCybX5N9NwM6aZN2OttokDBpHq6kPNOjJdtR26JLtrdHJekd9T9MeqdFzzMID0kmnvd-ho9ZR48dxdjY9UW3uZ5ud6eRwHr2z-ht93GNAGvd-HrqDyRSsDws9WPx-So57PUT8_PqekLtfP2-3f4qr69-X2x9XhYENpKLqeF_Ktq9QwaERCEJykwukYaCqHnQLMl9Gtcqwmnd1V4oSmUaBdQUn5OuL7xT8_YwxNaONBodBO_RzbPimrFW-Zc3egXIpQdRKZBReUBN8jAH7Jn9u1OGp4axZ0mre0moOaTVLWnnqy-uCuR2x-z_zFg88A_VlkZQ</recordid><startdate>201609</startdate><enddate>201609</enddate><creator>José, Ricardo J</creator><creator>Brown, Jeremy S</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QL</scope><scope>7T5</scope><scope>C1K</scope><scope>H94</scope></search><sort><creationdate>201609</creationdate><title>Predicting bacteraemia or rapid identification of the causative pathogen in community acquired pneumonia: where should the priority lie?</title><author>José, Ricardo J ; Brown, Jeremy S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c383t-5d1f26bf5e93f26bf4e3461c1c136c0395f3ab369309b9c071d7d242e0ae4e753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Clostridium difficile</topic><topic>Pseudomonas aeruginosa</topic><topic>Staphylococcus aureus</topic><topic>Streptococcus pneumoniae</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>José, Ricardo J</creatorcontrib><creatorcontrib>Brown, Jeremy S</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>The European respiratory journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>José, Ricardo J</au><au>Brown, Jeremy S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predicting bacteraemia or rapid identification of the causative pathogen in community acquired pneumonia: where should the priority lie?</atitle><jtitle>The European respiratory journal</jtitle><addtitle>Eur Respir J</addtitle><date>2016-09</date><risdate>2016</risdate><volume>48</volume><issue>3</issue><spage>619</spage><epage>622</epage><pages>619-622</pages><issn>0903-1936</issn><eissn>1399-3003</eissn><abstract>Community-acquired pneumonia (CAP) remains amongst the most common causes of infectious disease-related death worldwide. However, despite its clinical importance the existing routine microbiology tests for CAP pathogens have significant limitations, lacking sensitivity for identifying the causative pathogen and only altering management in a minority of patients. For example, blood cultures identify a pathogen in less than or equal to 10% of CAP cases [1, 2] and results are usually only available after 24h. Therefore, clinicians are still required to prescribe broad-spectrum antibiotics for the first 24-72h, which is the period of highest risk for clinical deterioration and death [3, 4]; even when bacteria are cultured this only rarely leads to a change in treatment and may miss co-infection [2, 5]. These limitations have led to suggestions that patients admitted with CAP do not require routine microbiological testing with management decisions based solely on clinical factors. However, not identifying the causative pathogens in CAP has important implications. From a public health perspective, not performing microbiological testing could result in failure to identify important changes in microbial aetiology or changes in anti-microbial resistance patterns. In the absence of microbiological testing all patients would be treated with prolonged broad-spectrum antibiotics that may not be required if, for example, Streptococcus pneumoniae was the causative pathogen, thereby unnecessarily increasing drug cost and potentially promoting the development of antimicrobial resistance or anti-microbial-related complications such as Clostridium difficile diarrhoea [6]. Finally, the relatively rare CAP patient infected with a drug-resistant pathogen, such as community-acquired methicillin-resistant Staphylococcus aureus or Pseudomonas aeruginosa, may not be identified, thus increasing the chance of a poor outcome.</abstract><cop>England</cop><pmid>27581406</pmid><doi>10.1183/13993003.00941-2016</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0903-1936
ispartof The European respiratory journal, 2016-09, Vol.48 (3), p.619-622
issn 0903-1936
1399-3003
language eng
recordid cdi_proquest_miscellaneous_1827920170
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Clostridium difficile
Pseudomonas aeruginosa
Staphylococcus aureus
Streptococcus pneumoniae
title Predicting bacteraemia or rapid identification of the causative pathogen in community acquired pneumonia: where should the priority lie?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T04%3A31%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predicting%20bacteraemia%20or%20rapid%20identification%20of%20the%20causative%20pathogen%20in%20community%20acquired%20pneumonia:%20where%20should%20the%20priority%20lie?&rft.jtitle=The%20European%20respiratory%20journal&rft.au=Jos%C3%A9,%20Ricardo%20J&rft.date=2016-09&rft.volume=48&rft.issue=3&rft.spage=619&rft.epage=622&rft.pages=619-622&rft.issn=0903-1936&rft.eissn=1399-3003&rft_id=info:doi/10.1183/13993003.00941-2016&rft_dat=%3Cproquest_cross%3E1827920170%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1816634794&rft_id=info:pmid/27581406&rfr_iscdi=true